Susan Joseph, MD
Type of study:
The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to a placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF..
The study will evaluate several outcomes measures including:
Please click the "Continue Session" button below to continue using the website. To end your session please click the "End Session" button below. After 5 minutes of inactivity your session will be terminated and you will be required to log in again.